MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chouabe, C.
Right arrow Articles by Lazdunski, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chouabe, C.
Right arrow Articles by Lazdunski, M.

Vol. 54, Issue 4, 695-703, October 1998

HERG and KvLQT1/IsK, the Cardiac K+ Channels Involved in Long QT Syndromes, Are Targets for Calcium Channel Blockers

Christophe Chouabe, Milou-Daniel Drici, Georges Romey, Jacques Barhanin, and Michel Lazdunski

Institut de Pharmacologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Sophia Antipolis, F-06560 Valbonne, France

We examined the effects of the calcium channel blockers nitrendipine, diltiazem, verapamil, bepridil, and mibefradil on the cloned HERG and KvLQT1/IsK K+ channels. These channels generate the rapid and slow components of the cardiac delayed rectifier K+ current, and mutations can affect them, which leads to long QT syndromes. When expressed in transfected COS cells, HERG is blocked in a concentration-dependent manner by bepridil (EC50 = 0.55 µM), verapamil (EC50 = 0.83 µM), and mibefradil (EC50 = 1.43 µM), whereas nitrendipine and diltiazem have negligible effects. Steady state activation and inactivation parameters are shifted to more negative values in the presence of the blockers. Similarly, KvLQT1/IsK is inhibited by bepridil (EC50 = 10.0 µM) and mibefradil (EC50 = 11.8 µM), while being insensitive to nitrendipine, diltiazem, or verapamil. These results demonstrate that both cloned K+ channels HERG and KvLQT1/IsK, which represent together the cardiac delayed rectifier K+ current, are sensitive targets to calcium channel blockers. This work may help in understanding the mechanisms of action of verapamil in certain ventricular tachycardia, as well as some of the deleterious adverse cardiac events associated with bepridil.


Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
S. B. Ganapathi, M. Kester, and K. S. Elmslie
State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy
Am J Physiol Cell Physiol, April 1, 2009; 296(4): C701 - C710.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
C. V. Remillard, D. D. Tigno, O. Platoshyn, E. D. Burg, E. E. Brevnova, D. Conger, A. Nicholson, B. K. Rana, R. N. Channick, L. J. Rubin, et al.
Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension
Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1837 - C1853.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
G. Thomas, M. J. Killeen, I. S. Gurung, P. Hakim, R. Balasubramaniam, C. A. Goddard, A. A. Grace, and C. L.-H. Huang
Mechanisms of ventricular arrhythmogenesis in mice following targeted disruption of KCNE1 modelling long QT syndrome 5
J. Physiol., January 1, 2007; 578(1): 99 - 114.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
G. Thomas, I. S. Gurung, M. J. Killeen, P. Hakim, C. A. Goddard, M. P. Mahaut-Smith, W. H. Colledge, A. A. Grace, and C. L.-H. Huang
Effects of L-type Ca2+ channel antagonism on ventricular arrhythmogenesis in murine hearts containing a modification in the Scn5a gene modelling human long QT syndrome 3
J. Physiol., January 1, 2007; 578(1): 85 - 97.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. M. McNulty, J. W. Kyle, G. M. Lipkind, and D. A. Hanck
An Inner Pore Residue (Asn406) in the Nav1.5 Channel Controls Slow Inactivation and Enhances Mibefradil Block to T-Type Ca2+ Channel Levels
Mol. Pharmacol., November 1, 2006; 70(5): 1514 - 1523.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. Czirjak and P. Enyedi
Zinc and Mercuric Ions Distinguish TRESK from the Other Two-Pore-Domain K+ Channels
Mol. Pharmacol., March 1, 2006; 69(3): 1024 - 1032.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
G. A. Gintant, Z. Su, R. L. Martin, and B. F. Cox
Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization and QT Safety
Toxicol Pathol, January 1, 2006; 34(1): 81 - 90.
[Abstract] [Full Text] [PDF]


Home page
J Biomol ScreenHome page
A. E. Dubin, N. Nasser, J. Rohrbacher, A. N. Hermans, R. Marrannes, C. Grantham, K. Van Rossem, M. Cik, S. R. Chaplan, D. Gallacher, et al.
Identifying Modulators of hERG Channel Activity Using the PatchXpress(R) Planar Patch Clamp
J Biomol Screen, March 1, 2005; 10(2): 168 - 181.
[Abstract] [PDF]


Home page
Mol. Pharmacol.Home page
M. M. McNulty and D. A. Hanck
State-Dependent Mibefradil Block of Na+ Channels
Mol. Pharmacol., December 1, 2004; 66(6): 1652 - 1661.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon
Pharmacology of cardiac potassium channels
Cardiovasc Res, April 1, 2004; 62(1): 9 - 33.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
R. Balasubramaniam, A. A Grace, R. C Saumarez, J. I Vandenberg, and C. L-H Huang
Electrogram prolongation and nifedipine-suppressible ventricular arrhythmias in mice following targeted disruption of KCNE1
J. Physiol., October 15, 2003; 552(2): 535 - 546.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Diochot, E. Loret, T. Bruhn, L. Beress, and M. Lazdunski
APETx1, a New Toxin from the Sea Anemone Anthopleura elegantissima, Blocks Voltage-Gated Human Ether-a-go-go-Related Gene Potassium Channels
Mol. Pharmacol., July 1, 2003; 64(1): 59 - 69.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
P. Benquet, J. Le Guen, Y. Pichon, and F. Tiaho
Differential Involvement of Ca2+ Channels in Survival and Neurite Outgrowth of Cultured Embryonic Cockroach Brain Neurons
J Neurophysiol, September 1, 2002; 88(3): 1475 - 1490.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. Lecchi, E. Redaelli, B. Rosati, G. Gurrola, T. Florio, O. Crociani, G. Curia, R. R. Cassulini, A. Masi, A. Arcangeli, et al.
Isolation of a Long-Lasting eag-Related Gene-Type K+ Current in MMQ Lactotrophs and Its Accommodating Role during Slow Firing and Prolactin Release
J. Neurosci., May 1, 2002; 22(9): 3414 - 3425.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Nattel
Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management?
Cardiovasc Res, May 1, 2002; 54(2): 347 - 360.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. Thomas, B. Gut, G. Wendt-Nordahl, and J. Kiehn
The Antidepressant Drug Fluoxetine Is an Inhibitor of Human Ether-A-Go-Go-Related Gene (HERG) Potassium Channels
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 543 - 548.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
S. Glaser, M. Steinbach, C. Opitz, U. Wruck, and F. X. Kleber
Torsades de pointes caused by Mibefradil
Eur J Heart Fail, October 1, 2001; 3(5): 627 - 630.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
D. Escande
Inhibition of repolarizing ionic currents by drugs
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K17 - K22.
[Abstract] [PDF]


Home page
Mol. Pharmacol.Home page
S. Zhang, S. Rajamani, Y. Chen, Q. Gong, Y. Rong, Z. Zhou, A. Ruoho, and C. T. January
Cocaine Blocks HERG, but Not KvLQT1+minK, Potassium Channels
Mol. Pharmacol., April 16, 2001; 59(5): 1069 - 1076.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
D. Thomas, G. Wendt-Nordahl, K. Röckl, E. Ficker, A. M. Brown, and J. Kiehn
High-Affinity Blockade of Human Ether-A-Go-Go-Related Gene Human Cardiac Potassium Channels by the Novel Antiarrhythmic Drug BRL-32872
J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 753 - 761.
[Abstract] [Full Text]


Home page
FASEB J.Home page
B. ROSATI, P. MARCHETTI, O. CROCIANI, M. LECCHI, R. LUPI, A. ARCANGELI, M. OLIVOTTO, and E. WANKE
Glucose- and arginine-induced insulin secretion by human pancreatic {beta}-cells: the role of HERG K+ channels in firing and release
FASEB J, December 1, 2000; 14(15): 2601 - 2610.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
L. Perchenet and O. Clément-Chomienne
Characterization of Mibefradil Block of the Human Heart Delayed Rectifier hKv1.5
J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 771 - 778.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Bénardeau, J. Weissenburger, L. Hondeghem, and E. A. Ertel
Effects of the T-Type Ca2+ Channel Blocker Mibefradil on Repolarization of Guinea Pig, Rabbit, Dog, Monkey, and Human Cardiac Tissue
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 561 - 575.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
A. A. Grace and A.J. Camm
Voltage-gated calcium-channels and antiarrhythmic drug action
Cardiovasc Res, January 1, 2000; 45(1): 43 - 51.
[Full Text] [PDF]


Home page
Circ. Res.Home page
S. Zhang, Z. Zhou, Q. Gong, J. C. Makielski, and C. T. January
Mechanism of Block and Identification of the Verapamil Binding Domain to HERG Potassium Channels
Circ. Res., May 14, 1999; 84(9): 989 - 998.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics